Objective To analyze the efficacy and safety of citalopram combined with pantoprazole and itopride in the treatment of reflux esophagitis.Methods A total of 100 patients with reflux esophagitis admitted from January 2020 to December 2022 were randomly divided into conventional group(50 cases,pantoprazole+itopride)and observation group(50 cases,citalopram+pantoprazole+itopride).The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was significantly higher than that in the conventional group,and the difference was statistically significant(P<0.05).After treatment,the scores of acid reflux,heartburn,epigastric distention and belching in the observation group were lower than those in the conventional group,and the differences were statistically significant(P<0.05).After treatment,the level of dopamine(DA)in the observation group was lower than that in the conventional group,and the levels of brain-derived neurotrophic factor(BDNF)and 5-hydroxytryptamine(5-HT)were higher than those in the conventional group,and the differences were statistically significant(P<0.05).After treatment,the frequency of electrogastrogram and the scores of Self-Rating Anxiety Scale(SAS)and Self-Rating Depression Scale(SDS)in the observation group were lower than those in the conventional group,and the World Health Organization Quality of Life-100(WHOQOL-100)score was higher than that in the conventional group,and the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups during treatment(P>0.05).Conclusion Citalopram combined with pantoprazole and itopride in the treatment of reflux esophagitis has an ideal effect,which is worthy of clinical promotion and application.
维普
万方数据
